GSK's ViiV Healthcare Completes Shareholding Restructuring, Pfizer Exits

summarizeSummary

GSK announced the completion of the ViiV Healthcare shareholding changes, with Pfizer exiting its investment and Shionogi increasing its stake, resulting in a $250 million special dividend for GSK and the extinguishment of a put option liability.

check_boxKey Events

• ViiV Healthcare Shareholding Restructuring Completed

  GSK, Pfizer, and Shionogi have finalized changes to the ViiV Healthcare shareholding, following initial announcements on January 20, 2026.

• Pfizer Exits ViiV Healthcare Investment

  Pfizer Inc. has completed its exit from its 11.7% economic interest in ViiV Healthcare, receiving $1.875 billion.

• Shionogi Increases Stake

  Shionogi & Co., Ltd. has increased its economic interest in ViiV Healthcare to 21.7% by investing $2.125 billion for new shares.

• GSK Maintains Majority Control and Receives Dividend

  GSK plc maintains its 78.3% majority-owned economic interest in ViiV Healthcare and received a special dividend of $250 million.

auto_awesomeAnalysis

This filing announces the completion of a significant corporate transaction for GSK's specialist HIV company, ViiV Healthcare. The restructuring sees Pfizer fully exit its investment, while Shionogi increases its stake to 21.7%. For GSK, this results in a $250 million special dividend and, importantly, the extinguishment of a put option liability previously held by Pfizer. This move solidifies GSK's majority control (78.3%) of ViiV Healthcare and improves its balance sheet by removing a significant liability, providing a positive financial outcome for the company.